On the contrary, I'm very interested in trading/charting, though rather in FOREX and DAX30, so thanks for your insight!
Yes, sure, feel my free to trade any bounce in any stock that I have mentioned.
To provide some context:
With CRMD, it is pretty much in the hands of the FDA what will happen next. I got in last year after their trial was halted early for efficacy (at .50 - 5:1 RS adjusted at around 2.50). Originally, the FDA required two trials, but their trial was very large and it showed a highly statistical reduction in CRBSIs (72% reduction vs. SOC heparin; p-value: 0.0006), so that they think that one trial in that area of huge unmet need will suffice to submit an NDA under the relatively new LPAD-pathway (and I agree, the FDA would be nuts if they required a second study under these circumstances and the excellent results - but who knows). I would agree with you that it will consolidate a little bit more before rising again.
With SCYX, they have quite a few shots in the anti-fungal space for different indications and already announced pretty interesting and encouraging interim results, especially against Candida auris, which becomes more and more problematic. (I think there was an article in the NYT about Candida auris recently). They surely will qualify for LPAD and given the unmet need, for me this is a kind of no-brainer BO candidate in 2021. (Of course IMHO). I like them; CEO is down-to-earth, competent, committed, heavily invested in his company at a much higher level without ever selling. ...Yes, here too, unless they announce more interim data, I think it will consolidate lower.
If you have the time, I'd be interested about hearing what you think about the chart of VSTM (without knowing about it fundamentally).
Cheers!
Yes, sure, feel my free to trade any bounce in any stock that I have mentioned.
To provide some context:
With CRMD, it is pretty much in the hands of the FDA what will happen next. I got in last year after their trial was halted early for efficacy (at .50 - 5:1 RS adjusted at around 2.50). Originally, the FDA required two trials, but their trial was very large and it showed a highly statistical reduction in CRBSIs (72% reduction vs. SOC heparin; p-value: 0.0006), so that they think that one trial in that area of huge unmet need will suffice to submit an NDA under the relatively new LPAD-pathway (and I agree, the FDA would be nuts if they required a second study under these circumstances and the excellent results - but who knows). I would agree with you that it will consolidate a little bit more before rising again.
With SCYX, they have quite a few shots in the anti-fungal space for different indications and already announced pretty interesting and encouraging interim results, especially against Candida auris, which becomes more and more problematic. (I think there was an article in the NYT about Candida auris recently). They surely will qualify for LPAD and given the unmet need, for me this is a kind of no-brainer BO candidate in 2021. (Of course IMHO). I like them; CEO is down-to-earth, competent, committed, heavily invested in his company at a much higher level without ever selling. ...Yes, here too, unless they announce more interim data, I think it will consolidate lower.
If you have the time, I'd be interested about hearing what you think about the chart of VSTM (without knowing about it fundamentally).
Cheers!
